An interventional study of Platelet-rich Plasma (PRP) and Hyaluronic Acid in Osteoarthritis, Knee, sponsored by Rush University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-14.
Sponsored by Rush University Medical Center · Not applicable, Interventional, and Treatment
In this, prospective, double-blind study, patients with mild to moderate symptomatic knee osteoarthritis will be randomized to receive either a series of leukocyte poor, platelet-rich plasma or hyaluronic acid injections under ultrasound guidance. Clinical data in the form of subjective outcome measures will be collected pre-treatment and at four time intervals across a 1-year period. Synovial fluid will also collected for analysis of pro- and anti-inflammatory markers pre-treatment, and at 12 and 24 weeks.
The objective of this double-blind prospective randomized clinical trial is to compare the effects of PRP to HA in patients with mild to moderate OA using biologic and clinical correlates of outcomes associated with the treatment of OA. The investigators will test the null hypothesis that there are no differences in clinical outcomes as measured by validated clinical scoring systems for OA, nor is there any difference in intra-articular biology between groups of patients treated with HA and those treated with PRP over time.
This study was a prospective, randomized, double blind, comparative clinical trial with an allocation ratio of 1:1 that underwent IRB approval at the principal institution. Between 2011 and 2014 patients will be screened for participation. All comers with a diagnosis of osteoarthritis of the knee between 18 and 80 years of age will be screened.
Treatment and Evaluation Patients who meet inclusion criteria will be randomized via an electronic randomization process into two groups: one receiving intra-articular PRP and the other, intra-articular HA. Non-clinical staff will perform randomization, clinical staff performed the injections, and results and analyses will be performed by the primary research team. Patients and the primary research team performing analysis will be blinded to assignments. All patients will undergo a 10 ml blood draw for PRP preparation and a 3 ml peripheral blood draw for a complete blood count with leukocyte differential. This will be performed on patients who received HA to maintain patient blinding and to characterize the peripheral white blood cells (WBC) and platelet counts. A complete blood count (CBC) will be completed on PRP prior to injection to evaluate the fold increase in platelet concentration and to confirm rarity of red white blood cells. A synovial fluid aspirate of approximately 2cc will be performed under ultrasound guidance just prior to each PRP or HA injection for ELISA analysis of basal and post-treatment intra-articular environment. After treatment, patients will be instructed to limit the use of the leg for at least 24 hours and use cold therapy/icing for discomfort. During this treatment period rest or mild exertion activities (such as exercise bike, aquatic therapy) are recommended, followed by gradual return to sports or recreational activities as tolerated.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 111 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Rush University Medical Center is the lead sponsor of 394 studies on the registry; 61 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
Biological: Hyaluronic Acid
Platelet-rich plasma administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of leukocyte poor, buffer/additive free, singe spin, platelet-rich plasma averaging 4mL in volume.
Biological: Platelet-rich Plasma (PRP)
International Knee Documentation Committee Score (IKDC
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
Time frame: This will be assessed as a change from pre-treatment visit to 1 year post treatment.
Visual Analogue Scale (VAS)
This is a scale from 1-100, 100 being the worst pain imaginable and 1 being no pain at all that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
Time frame: This will be assessed as a change from pre-treatment visit to 1 year post treatment.
Western Ontario and McMaster Universities Arthritis Index
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
Time frame: This will be assessed as a change from pre-treatment visit to 1 year post treatment. 6-weeks post-treatment, 6-months post treatment, and finally at 1-year post treatment will be documented for the purpose of trending data.
Lysholm Knee Score
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
Time frame: This will be assessed as a change from pre-treatment visit to 1 year post treatment.
Biologic Testing of Synovial Fluid Via ELISA Assays
ELISA analysis will be performed for the following biological markers: IL-1β, IL-1ra, IL-6, IL-8, TNFα
Time frame: Primary outcome will be change from pre-treatment to 6-month post treatment.
| Milestone | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| Started | 59 | 52 |
| Completed | 59 | 52 |
| Not completed | 0 | 0 |
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
| units on a scale | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| International Knee Documentation Committee Score (IKDC | 65.5 ± 3.6 | 55.8 ± 3.8 |
This is a scale from 1-100, 100 being the worst pain imaginable and 1 being no pain at all that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
| units on a scale | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| Visual Analogue Scale (VAS) | 57.3 ± 3.8 | 44 ± 4.6 |
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
| units on a scale | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| Western Ontario and McMaster Universities Arthritis Index | 4 ± 0.6 | 3.02 ± 0.48 |
This is a scale from 1-100, 100 being high function and 1 being very poor function that will be assessed via paper questionnaire at the delineated time intervals. The Primary outcome assessed will be at an average of 1-year post treatment.
| units on a scale | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| Lysholm Knee Score | 55.8 ± 3.8 | 65.5 ± 3.6 |
ELISA analysis will be performed for the following biological markers: IL-1β, IL-1ra, IL-6, IL-8, TNFα
| units on a scale | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) |
|---|---|---|
| Biologic Testing of Synovial Fluid Via ELISA Assays | 0.14 ± 0.005 | 0.34 ± 0.16 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hyaluronic Acid (HA) | — | 0/59 (0%) | 0/59 (0%) |
| Platelet-rich Plasma (PRP) | — | 0/52 (0%) | 0/52 (0%) |
| Age, Continuous(years) | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) | Total |
|---|---|---|---|
| Mean | 56.8 ± 10.5 | 55.9 ± 10.4 | 56.3 ± 10.4 |
| Sex: Female, Male(Participants) | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) | Total |
|---|---|---|---|
| Female | 30 | 21 | 51 |
| Male | 20 | 28 | 48 |
| BMI(kg/m^2) | Hyaluronic Acid (HA) | Platelet-rich Plasma (PRP) | Total |
|---|---|---|---|
| Mean | 29 ± 6.4 | 27.4 ± 3.9 | 28.2 ± 5.1 |
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center